A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
Systemic Lupus ErythematosusCutaneous Lupus ErythematosusSjogren's SyndromeSystemic SclerosisPolymyositisDermatomyositis
Interventions
DRUG

VIB7734

Participants will receive VIB7734 via injection.

DRUG

Placebo

Participants will receive placebo matching to VIB7734 via injection.

Trial Locations (30)

11021

Viela Bio Investigative Site, Great Neck

16635

Viela Bio Investigative Site, Duncansville

19104

Viela Bio Investigative Site, Philadelphia

27713

Viela Bio Investigative Site, Durham

28204

Viela Bio Investigative Site, Charlotte

30046

Viela Bio Investigative Site, Lawrenceville

32216

Viela Bio Investigative Site, Jacksonville

33014

Viela Bio Investigative Site, Miami Lakes

33016

Viela Bio Investigative Site, Hialeah

33309

Viela Bio Investigative Site, Fort Lauderdale

33710

Viela Bio Investigative Site, St. Petersburg

35294

Viela Bio Investigative Site, Birmingham

36201

Viela Bio Investigative Site, Anniston

38119

Viela Bio Investigative Site, Memphis

75013

Viela Bio Investigative Site, Allen

75150

Viela Bio Investigative Site, Mesquite

90022

Viela Bio Investigative Site, Los Angeles

91786

Viela Bio Investigative Site, Upland

06810

Viela Bio Investigative Site, Danbury

Unknown

Viela Bio Investigative Site, Bialystok

Viela Bio Investigative Site, Bydgoszcz

Viela Bio Investigative Site, Krakow

Viela Bio Investigative Site, Poznan

Viela Bio Investigative Site, Rzeszów

Viela Bio Investigative Site, Warsaw

Viela Bio Investigative Site, Wroclaw

Viela Bio Investigative Site, Barcelona

Viela Bio Investigative Site, Bilbao

Viela Bio Investigative Site, Madrid

Viela Bio Investigative Site, Seville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03817424 - A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis | Biotech Hunter | Biotech Hunter